Trial Profile
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2021
Price :
$35
*
At a glance
- Drugs GC 3110A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GC Pharma
- 15 Mar 2021 Primary endpoint (Seroprotection rate for HI antibody after final injection) has been met as per the results published in the Vaccine.
- 15 Mar 2021 Primary endpoint (Seroconversion rate for HI antibody after final injection) has been met as per the results published in the Vaccine.
- 15 Mar 2021 Status changed from not yet recruiting to completed as per the results published in the Vaccine.